It has been proposed that Leronlimab's s/c Phase III s/c trial, probably has more critical patients than severe, because critical would be more motivated to volunteer, considering their dire condition. I tend to agree with that.

So that will result in more deaths and a probable better p value for leronlimab. Considering that 87 deaths were announced yesterday by Nader, so far in the s/c trial, if say 37 of those were in the leronlimab folks (based upon our old eIND data of 14.5% deaths) and 50 deaths in the placebo group, that would give a reduction of death above 60% for leronlimab. That is high, most investors and analysts don't think it will be that high. However, as a starting point for discusion, I think these numbers highlite the high probability of success in achieving Statistical Significance and an acceptable p value and a FDA EUA.